Gyre Therapeutics logo

Gyre Therapeutics Share Price Today

(NASDAQ: GYRE)

Gyre Therapeutics share price is $11.12 & ₹967.10 as on 6 Mar 2025, 2.30 'hrs' IST

$11.12

0.22

(2.02%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Gyre Therapeutics share price in Dollar and Rupees. Guide to invest in Gyre Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Gyre Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Gyre Therapeutics share price movements

  • Today's Low: $10.51
    Today's High: $11.39

    Day's Volatility :7.69%

  • 52 Weeks Low: $8.26
    52 Weeks High: $21.17

    52 Weeks Volatility :60.97%

Gyre Therapeutics (GYRE) Returns

PeriodGyre Therapeutics IncIndex (Russel 2000)
3 Months
6.26%
0.0%
6 Months
-5.92%
0.0%
1 Year
-46.23%
0.0%
3 Years
65.23%
-11.6%

Gyre Therapeutics (GYRE) Key Statistics

in dollars & INR

Previous Close
$10.9
Open
$10.77
Today's High
$11.385
Today's Low
$10.51
Market Capitalization
$935.5M
Today's Volume
$64.4K
52 Week High
$21.165
52 Week Low
$8.26
Revenue TTM
$105.0M
EBITDA
$11.8M
Earnings Per Share (EPS)
$-1.0
Profit Margin
-84.57%
Quarterly Earnings Growth YOY
-0.74%
Return On Equity TTM
-85.32%

How to invest in Gyre Therapeutics Stock (GYRE) from India?

It is very easy for Indian residents to invest directly in Gyre Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Gyre Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Gyre Therapeutics or GYRE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Gyre Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Gyre Therapeutics shares which would translate to 0.078 fractional shares of Gyre Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Gyre Therapeutics, in just a few clicks!

Returns in Gyre Therapeutics (GYRE) for Indian investors in Rupees

The Gyre Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Gyre Therapeutics investment value today

Current value as on today

₹58,721

Returns

₹41,279

(-41.28%)

Returns from Gyre Therapeutics Stock

₹46,228 (-46.23%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Gyre Therapeutics (GYRE)

0%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Gyre Therapeutics Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Gyre Therapeutics

Sell

    0%Buy

    50%Hold

    50%Sell

Based on 6 Wall street analysts offering stock ratings for Gyre Therapeutics(by analysts ranked 0 to 5 stars)

Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
0
0
0
Hold
3
3
3
Sell
3
3
3

Insights on Gyre Therapeutics Stock (Ticker Symbol: GYRE)

  • Price Movement

    In the last 1 year, GYRE stock has moved down by -46.2%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 25.22M → 25.48M (in $), with an average increase of 1.0% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 3.52M → 5.00M (in $), with an average increase of 29.5% per quarter
  • GYRE vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 112.7%
  • Price to Sales

    ForGYRE every $1 of sales, investors are willing to pay $8.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Gyre Therapeutics Technicals Summary

Sell

Neutral

Buy

Gyre Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Gyre Therapeutics (GYRE) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gyre Therapeutics Inc logo
-6.4%
-5.92%
-46.23%
65.23%
65.23%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gyre Therapeutics Inc logo
NA
NA
NA
0.0
-0.85
0.1
NA
0.74
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gyre Therapeutics Inc logo
Sell
$935.5M
65.23%
NA
-84.57%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Gyre Therapeutics

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Organization
Gyre Therapeutics
Employees
593
CEO
Dr. Han Ying Ph.D.
Industry
Miscellaneous

Management People of Gyre Therapeutics

NameTitle
Mr. Songjiang Ma
President & Chairman
Dr. Han Ying Ph.D.
CEO & Director
Ms. Ruoyu Chen
Chief Financial Officer
Mr. Weiguo Ye
Chief Operating Officer
Ms. Seline E. Miller CPA
Senior Vice President of Finance

Important FAQs about investing in GYRE Stock from India :

What is Gyre Therapeutics share price today?

Gyre Therapeutics share price today stands at $11.12, Open: $10.77 ; Previous Close: $10.90 ; High: $11.39 ; Low: $10.51 ; 52 Week High: $21.17 ; 52 Week Low: $8.26.

The stock opens at $10.77, after a previous close of $10.90. The stock reached a daily high of $11.39 and a low of $10.51, with a 52-week high of $21.17 and a 52-week low of $8.26.

Can Indians buy Gyre Therapeutics shares?

Yes, Indians can invest in the Gyre Therapeutics (GYRE) from India.

With INDmoney, you can buy Gyre Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Gyre Therapeutics at zero transaction cost.

How can I buy Gyre Therapeutics shares from India?

It is very easy to buy Gyre Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Gyre Therapeutics (GYRE) be purchased?

Yes, you can buy fractional shares of Gyre Therapeutics with INDmoney app.

What are the documents required to start investing in Gyre Therapeutics stocks?

To start investing in Gyre Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Gyre Therapeutics Stock (GYRE)?

Today’s highest price of Gyre Therapeutics (GYRE) is $11.39.

Today’s lowest price of Gyre Therapeutics (GYRE) is $10.51.

What is today's market capitalisation of Gyre Therapeutics?

Today's market capitalisation of Gyre Therapeutics GYRE is 935.5M

What is the 52 Week High and Low Range of Gyre Therapeutics Stock (GYRE)?

  • 52 Week High

    $21.17

  • 52 Week Low

    $8.26

What are the historical returns of Gyre Therapeutics (GYRE)?

  • 1 Month Returns

    -6.4%

  • 3 Months Returns

    -5.92%

  • 1 Year Returns

    -46.23%

  • 5 Years Returns

    65.23%

Who is the Chief Executive Officer (CEO) of Gyre Therapeutics ?

Dr. Han Ying Ph.D. is the current Chief Executive Officer (CEO) of Gyre Therapeutics.